Minocycline: therapeutic potential in psychiatry - Test2 - elhamkhani - TriplyDB

Minocycline: therapeutic potential in psychiatry

Minocycline: therapeutic potential in psychiatry

http://www.wikidata.org/entity/Q22241418

about

Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders Cognitive remission: a novel objective for the treatment of major depression?Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder The neuroimmunology of schizophrenia Profile of minocycline and its potential in the treatment of schizophrenia Neuroimmune basis of methamphetamine toxicity Tumor necrosis factor-α modulates cerebral aneurysm formation and rupture.Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.Biomarkers and clinical staging in psychiatry Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat.Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?Microglial activation and progressive brain changes in schizophrenia.Potential therapeutic approaches for Angelman syndrome.Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.Biotic acts of antibiotics Mind and body: how the health of the body impacts on neuropsychiatry.Sleep and inflammatory markers in different psychiatric disorders.Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges.Modeling schizophrenia: uncovering novel therapeutic targets.Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder.Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia.Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.Inhibition of brain retinoic acid catabolism: a mechanism for minocycline's pleiotropic actions?Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.Antipsychotic-like effect of minocycline in a rat model.Staging bipolar disorder: clinical, biochemical, and functional correlates.Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways.Microglial inhibitory effect of ginseng ameliorates cognitive deficits and neuroinflammation following traumatic head injury in rats.Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia.Anti-inflammatory effects of minocycline are mediated by retinoid signaling Minocycline Attenuates Stress-Induced Behavioral Changes via Its Anti-inflammatory Effects in an Animal Model of Post-traumatic Stress Disorder

P2860

Q26767489-A27018F1-3E23-4F85-9DB9-FD81D12587F8 Q26775386-07823C65-56D6-44BD-906D-88B467F96FAF Q26782989-4B58B326-864B-4872-8DC1-BD99A790E148 Q26859392-F50D8FF3-D73E-4327-ADC9-C286D35D4E9A Q26864400-EFF2AEC6-1CC8-4F2A-8A79-83A213461052 Q28247084-215A64A3-D460-4389-8B4F-A35450CCA584 Q30457213-EACDFA66-BF03-441C-9B01-B629A99B71B4 Q34384181-D3D6F16F-21F2-4F11-8163-03A1560E1C60 Q34447051-3A27FE39-F43F-4E3F-9660-6B7643E7A07C Q34464608-4DAAF115-C77B-40BD-A867-FDD1945C5368 Q34524383-68056ECA-C1CA-4DAA-947B-7B5D96B36DF9 Q34678136-AA567C6C-90D8-4FB6-BFD2-BC58634D7978 Q34942602-633AC626-EEA1-4911-824A-062B90480139 Q35565011-4A165C89-6978-4FBB-A5B4-74532EB4E0FD Q36546971-417849D3-C84E-451D-98DA-49C225F69203 Q36992786-E5E39A70-DD31-4B1F-A2A0-C7C9519C6207 Q37052393-539C86DE-DB9D-4272-B489-54A44F87B777 Q37101851-75594483-ECC5-47D7-88E9-C6E3CCE7C5D0 Q37399776-5606E93E-A3D3-4314-98B9-85BFB4E79EA8 Q37614680-B62FABAB-66C1-4E9E-B71C-E9A574B72003 Q37639334-B77A544F-2C30-4AD7-A130-11BD7D04C754 Q38066958-28CD660A-6562-4739-9D70-E66023FE214E Q38125218-A6A8F081-7D63-48B4-A000-C232E12EB530 Q38150488-60665BAF-DF9E-47CD-8BE8-9CB449099A6D Q38209914-11E43FC0-FEEF-4E54-9D9F-32B9BE64A024 Q38867020-0076C452-3110-4074-85EB-718B36BFA3A8 Q40208014-51F60239-8E5D-41BA-A130-F638290BFAC9 Q43015622-0491F49E-CDE5-4927-B95E-380665D538C4 Q45751196-0C8B0DD1-18CC-467D-94EC-7C2D2BF40BEF Q47704592-091B6DDC-1574-4690-8A7A-014B3BB710EC Q47861374-DFC838B5-E962-408C-90F3-91033B81AD6D Q47970067-137FC93F-7D4D-4ED1-A3EC-38AC55C36C51 Q49012056-EB494E48-504D-49CA-BA8E-81BDCA5528C3 Q50653774-73E25B70-26A8-4675-AF73-31B321B05A39 Q58706730-1B3E50A5-53DD-45D7-BDD7-D07C6AAF8C7A Q59128390-D4A33FA3-2F21-43D8-9F32-D93F6CD7BD59

P2860

Minocycline: therapeutic potential in psychiatry

http://www.wikidata.org/entity/Q22241418

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Minocycline: therapeutic potential in psychiatry

@ast

Minocycline: therapeutic potential in psychiatry

@en

Minocycline: therapeutic potential in psychiatry

@en-gb

Minocycline: therapeutic potential in psychiatry

@fr

Minocycline: therapeutic potential in psychiatry

@nl

type

label

Minocycline: therapeutic potential in psychiatry

@ast

Minocycline: therapeutic potential in psychiatry

@en

Minocycline: therapeutic potential in psychiatry

@en-gb

Minocycline: therapeutic potential in psychiatry

@fr

Minocycline: therapeutic potential in psychiatry

@nl

altLabel

Minocycline

@en

prefLabel

Minocycline: therapeutic potential in psychiatry

@ast

Minocycline: therapeutic potential in psychiatry

@en

Minocycline: therapeutic potential in psychiatry

@en-gb

Minocycline: therapeutic potential in psychiatry

@fr

Minocycline: therapeutic potential in psychiatry

@nl

P1433

Q22241418-F44DADAA-7602-4D67-A3B3-E60ECEC93920

P1476

Q22241418-DB5D3C45-1060-4500-98AD-1204AFE22FD1

P2093

Q22241418-61457AE0-4BB7-4581-8DD4-02330AF6432A

Q22241418-AC314C9C-4772-47FD-B836-887D9BB9916F

Q22241418-D90856A3-921A-44F3-A63D-12F461A37074

P2860

Q22241418-0159726F-562C-4B79-A310-BB457EA6450E

Q22241418-05D71D88-85C4-4E8F-92F5-ACD930B936FD

Q22241418-05FF8C90-4909-4470-8EBC-21706114FE8C

Q22241418-0EA9FD75-CE0D-4DA0-8791-EF95D9A34421

Q22241418-0EE20E62-72C8-46ED-AABF-636795AD58D4

Q22241418-0EE46C4C-D39A-4D99-8894-B836CC9F735D

Q22241418-116C2572-9D52-4FB8-82AC-BF15AAF4DB28

Q22241418-147AAFD5-6906-4432-A7CA-310B4E71A210

Q22241418-1BFBDB29-0E3B-479D-957C-88DC344F75E5

Q22241418-20823785-3A88-483D-A5DA-ACEEDB1093A4

P2888

Q22241418-2711C688-0976-4B8F-B7F2-A12A8DE29ABB

P304

Q22241418-3B7453D1-C274-4CBC-AB31-90AE60760214

P31

Q22241418-E2E0F582-B348-4BB3-9EA6-68598D2E4748

P356

Q22241418-3A4504B2-92EC-4BB8-9537-1E68D34EB931

P407

Q22241418-214055AE-140F-44F9-A756-E20ADE774BE9

P433

Q22241418-C7C0405C-88AA-45FC-8151-1A36EBABDB73

P478

Q22241418-94E819AE-8D24-4932-A53A-C6EEE18D8B26

P50

Q22241418-2DC359AC-8E6D-4538-B5E0-5A2FC2C4F2A8

P577

Q22241418-8CC17DE7-CCC6-4256-B072-9798B43F766C

P5875

Q22241418-04040CD9-7F62-43A2-8187-9B1764D0D409

P6179

Q22241418-5D1CB42A-F30E-444A-A278-FA4F758E2BC8

P698

Q22241418-4211D5E2-3E0C-4AAF-A429-FEC1E05F41C2

P921

Q22241418-dc0e228d-4c86-4178-a876-08b0d4a030ad

P356

11632000-000000000-00000

P1433

P1476

Minocycline

@en

P2093

Francesco Giorlando

http://www.w3.org/2001/XMLSchema#string

João Data-Franco

http://www.w3.org/2001/XMLSchema#string

Olivia M. Dean

http://www.w3.org/2001/XMLSchema#string

P2860

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

Placebo-controlled trial of cytisine for smoking cessation

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Altered expression of neurotrophic factors in patients with major depression

Oxidative pathways as a drug target for the treatment of autism

Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: Roles of Bcl-2 and thioredoxin

Oxidative stress and neurodegeneration: where are we now?

A meta-analysis of cytokines in major depression

Inflammation is detrimental for neurogenesis in adult brain

P2888

11632000-000000000-00000

P304

391-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11632000-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223967920

http://www.w3.org/2001/XMLSchema#string

P6179

1011511445

http://www.w3.org/2001/XMLSchema#string

P698

22486246

http://www.w3.org/2001/XMLSchema#string

P921